TABLE 2

Incidence of AKI in unmatched and matched cohortsa

OutcomeUnmatched cohortMatched cohort
No. (%) of patientsP valueNo. (%) of patientsP value
VAN-TZP (n = 3,605)VAN-FEP (n = 588)VAN-TZP (n = 1,633)VAN-FEP (n = 578)
Any AKI771 (21.4)74 (12.6)<0.0001349 (21.4)72 (12.5)<0.0001
Risk422 (11.7)44 (7.5)0.003179 (11.0)42 (7.3)0.01
Injury244 (6.8)21 (3.6)0.004113 (6.9)21 (3.6)0.006
Failure105 (2.9)9 (1.5)0.0857 (3.5)9 (1.6)0.03
  • a FEP, cefepime; TZP, piperacillin-tazobactam; VAN, vancomycin.